|Dr. Kevin C. Gorman Ph.D.||Chief Exec. Officer and Director||972.52k||337.25k||59|
|Dr. Christopher F. O'Brien M.D.||Chief Medical Officer||758.71k||N/A||60|
|Dr. Haig P. Bozigian Ph.D.||Chief Devel. Officer||632.78k||N/A||59|
|Mr. Eric S. Benevich||Chief Commercial Officer||607.86k||N/A||52|
|Mr. Timothy P. Coughlin CPA||Exec. Officer||666.37k||N/A||50|
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The companys lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womens health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinsons disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the companys research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for womens and mens health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinsons disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 7; Compensation: 2.